LATEST NEWS
RTTNews menu
News News
Latest Headline Latest Headlines
Quick Facts Quick Facts
Breaking News Breaking News
Top Stories Top Stories
Biotech News Biotech News  New
Health News Health News
Earnings News Earnings News
Politics Politics
US Policy US Policy
General General
Commodities Commodities
Canadian Canadian
UK UK
Indian Indian
Wallstreet Events Wallstreet Events
Slide Shows Slide Shows
Technology news Technology
Software News Software
Entertainment News Entertainment
Manufacturing News Manufacturing
Food & Beverages News Food & Beverages
Banking News Banking
Automotive News Automotive
Aerospace News Aerospace
Agriculture News Agriculture
Energy News Energy
More Industry News More
US Economic News US Economic News
European Economic News European Economic News
Asian Economic News Asian Economic News
All Economic News All Economic News
FX Top Stories FX Top Stories
Currency Alerts Currency Alerts
Mkt Sensitive News Mkt Sensitive News
Politics Politics
European Mkt Updates European Mkt Updates
Asian Mkt Updates Asian Mkt Updates
Treasury Mkt Updates Treasury Mkt Updates
Top Story Top Story
TV News TV News
Movie Reviews Movie Reviews
DVD Releases DVD Releases
Box Office Box Office
Slide Shows Slide Shows
All Genres All Genres
Pop Pop
Rock Rock
Classic Rock Classic Rock
Rap/Hip-Hop Rap/Hip-Hop
Country Country
Alternative Alternative
Oldies Oldies
DVD Calendar DVD Calendar
Movie Calendar Movie Calendar
Concert Calendar Concert Calendar
Album Calendar Album Calendar
Business News Business News
Commentary/Analysis Commentary/Analysis
Daily Market Analysis Daily Market Analysis
US Market Update US Market Updates
US Commentary US Commentary
Asian Commentary Asian Commentary
European Commentary European Commentary
Canadian Commentary Canadian Commentary
Indian Commentary Indian Commentary
Sector/Market Trends Sector/Market Trends
Stock Alerts Stock Alerts
Stocks To Watch Stocks To Watch
Active Traders Active Traders
Before the Bell Before the Bell
$5 and Under $5 and Under
After the Bell After the Bell
Intraday Updates Intraday Updates
IPOs IPOs
Hot Stocks Hot Stocks
Science & Technology Science & Technology
Arts & Leisure Arts & Leisure
Politics & Policy Politics & Policy
Money Money
Earnings Calendars Earnings Calendars
Upcoming Earnings Upcoming Earnings
Latest Earnings Latest Earnings
Pos Pre Announcements Pos Pre Announcements
Neg Pre Announcements Neg Pre Announcements
Corporate Calendars Corporate Calendars
Stock Splits Stock Splits
Stock Buybacks Stock Buybacks
Dividend Calendar Dividend Calendar
Conferebce Calls Conference Calls
FDA Drug Approvals FDA Drug Approvals
FDA Device Approvals FDA Device Approvals
Mergers & Acquisitions Mergers & Acquisitions
Ratings Changes Ratings Changes
Upgrades Upgrades
Downgrades Downgrades
Coverage Initiations Coverage Initiations
Coverage Reiterated Coverage Reiterated
All Videos All Videos
Market Commentary Market Commentary
Top Stories Top Stories
Political News Political News
Corporate News Corporate News
Entertainment News Entertainment News
Top Stories Top Stories
Earnings Earnings
Market Commentary Market Commentary
Economic News Economic News
Corporate News Corporate News
Forex Forex News
Interviews Interviews
Growth and Value Stocks Growth and Value Stocks
RTT NewsStream RTT NewsStream
Economic Calendar Economic Calendar
RTT DeskAlert RTT DeskAlert
Mobile Mobile

Follow Us
RTTNews on Twitter RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube


Breaking News

FDA Okays Merck's Janumet XR For Type 2 Diabetes - Update

 SHARE
FONT-SIZE

2/2/2012 4:51 PM ET
(RTTNews) - Merck & Co. Inc. (MRK: News ) said Thursday the US Food and Drug Administration has approved its Janumet XR tablets as a new treatment for type 2 diabetes. The drug will be available in U.S. pharmacies in the next several weeks.

Janumet XR combines sitagliptin, which is the active component of Merck's blockbuster drug Januvia (sitagliptin), with extended-release metformin.

In Merck's fourth quarter 2011, Januvia sales rose 42 percent from last year to $960 million, while Janumet sales improved 34 percent to $386 million.

Janumet XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both sitagliptin and extended-release metformin is appropriate.

The drug is not recommended for use in type 1 diabetes or for the treatment of diabetic ketoacidosis. It has not been studied in patients with a history of pancreatitis.

"Janumet XR is a new treatment that adds once-daily convenience to the powerful efficacy of Janumet for patients with type 2 diabetes," said Barry Goldstein, vice president, Diabetes and Endocrinology, Merck.

"This is important because many patients with type 2 diabetes require treatment with multiple drugs to maintain blood sugar control, and Janumet XR is a new option to help more patients get to their glucose goals."

Janumet XR targets three key defects of diabetes: insulin deficiency from pancreatic beta cells, insulin resistance, and overproduction of glucose by the liver.

The labeling for Janumet XR contains a boxed warning for lactic acidosis, a rare, but serious complication attributed to metformin accumulation.

The drug is also contraindicated in patients with renal impairment; hypersensitivity to metformin HCl; acute metabolic acidosis; history of a serious hypersensitivity reaction to Janumet XR or sitagliptin.

The approval for Janumet XR was based upon a double-blind, placebo-controlled study of 1,091 patients who did not respond adequately to diet and exercise. Results showed that co-administration of metformin immediate-release and sitagliptin twice-daily resulted in a reduction of blood sugar relative to placebo.

The most common adverse reactions reported with sitagliptin and metformin immediate-release as initial therapy compared to metformin immediate-release alone were diarrhea, upper respiratory infection and headache.

Janumet XR is priced comparable to both Januvia and Janumet ((sitagliptin/metformin hydrochloride), on a per-daily-dose basis, Merck said in a statement.

MRK is trading on the NYSE at $38.50, down $0.13 or 0.34%, on a volume of 16.7 million shares.

To receive FREE breaking news email alerts for Merck & Co Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com


FREE Newsletters, Analysis & Alerts

 

Stay ahead of the markets with our FREE daily Newsletters and real-time breaking News Alerts. You get all the key economic/earnings news, stock/currency alerts, analysts actions, what to expect for the day ahead,etc

Copyright © 2012 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.